Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,222 | $12,269 | $11,201 | $12,342 |
| % Growth | -0.4% | 9.5% | -9.2% | – |
| Cost of Goods Sold | $4,156 | $4,199 | $3,861 | $4,918 |
| Gross Profit | $8,066 | $8,070 | $7,340 | $7,424 |
| % Margin | 66% | 65.8% | 65.5% | 60.2% |
| R&D Expenses | $2,528 | $2,580 | $2,257 | $2,788 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,789 | $1,713 | $1,584 | $2,105 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$96 | -$340 | -$22 | $0 |
| Operating Expenses | $4,221 | $3,953 | $3,819 | $4,893 |
| Operating Income | $3,845 | $4,117 | $3,521 | $2,531 |
| % Margin | 31.5% | 33.6% | 31.4% | 20.5% |
| Other Income/Exp. Net | -$731 | -$2,344 | -$550 | -$2,356 |
| Pre-Tax Income | $3,114 | $1,773 | $2,971 | $175 |
| Tax Expense | $919 | $460 | $509 | $99 |
| Net Income | $2,201 | $1,310 | $2,456 | $72 |
| % Margin | 18% | 10.7% | 21.9% | 0.6% |
| EPS | 1.08 | 0.64 | 1.21 | 0.036 |
| % Growth | 68.8% | -47.1% | 3,308.5% | – |
| EPS Diluted | 1.08 | 0.64 | 1.2 | 0.035 |
| Weighted Avg Shares Out | 2,036 | 2,035 | 2,031 | 2,029 |
| Weighted Avg Shares Out Dil | 2,039 | 2,038 | 2,037 | 2,037 |
| Supplemental Information | – | – | – | – |
| Interest Income | $161 | $139 | $138 | $0 |
| Interest Expense | $480 | $485 | $494 | $496 |
| Depreciation & Amortization | $1,026 | $1,029 | $1,028 | $1,869 |
| EBITDA | $4,620 | $3,287 | $4,492 | $2,540 |
| % Margin | 37.8% | 26.8% | 40.1% | 20.6% |